后COVID-19间歇性肺病患者肺细胞因子模式的动态变化:一个试点研究
Daniela Oatis1,2, Hildegard Herman3, Cornel Balta3
1Department of Infectious Disease, Faculty of Medicine, "Vasile Goldis" Western University of Arad, Arad, Romania.
在COVID后的间歇性肺病患者中,持续性炎症和IL-6和IL-8等细胞因子的升高被观察到长达六个月. 这项研究揭示了导致COVID-19感染后肺部痕的关键免疫驱动因素.
科学领域:
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
- 病毒学 病毒学
背景情况:
- 后COVID间歇性肺病 (ILD) 的发病因子,以肺部痕和功能衰退为特征,尚不清楚.
- 识别免疫系统失调对于了解和治疗SARS-CoV-2感染后的肺部并发症至关重要.
研究的目的:
- 调查COVID后ILD患者的支气管支气管洗液 (BAL) 中细胞因子和化学因子配置的时间变化.
- 为了确定潜在的免疫机制驱动肺纤维化和损伤后COVID-19.
主要方法:
- 分析了来自16名女性患者的48个BAL样本,这些患者在感染后的1,3个月和6个月内患有COVID后的ILD.
- 使用RT-PCR和ELISA测量细胞因子/化学因子表达.
- 与对照组进行了比较分析.
主要成果:
- 1个月后观察到IL-6,IL-8,干扰素-和瘤坏死因子α的显著增加,持续超过对照水平6个月.
- 持续升高的IL-10,IL-13和M2巨关联化学激素 (CCL13,CCL18) 表明正在进行的炎症和亲纤维活性.
- 在1个月后,观察到中性恋和中性恋细胞衰竭,同时 CD28.5 的时间依赖性减少.
结论:
- 这项研究强调了持续的炎症反应和在COVID后的ILD中特定的细胞因子/化学因子概况.
- 这些发现提供了对COVID-19后肺纤维变化的免疫过程的见解.
更多相关视频
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
08:05Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia
Published on: December 19, 2020
相关概念视频
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Pneumonia II: Pathophysiology
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
COPD: Management Using Bronchodilators and Corticosteroids
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
